Valuation: Inventiva

Capitalization 726M 852M 677M 636M 1.17B 76.9B 1.28B 7.88B 3.07B 36.32B 3.2B 3.13B 133B P/E ratio 2025 *
-6.07x
P/E ratio 2026 * -5.47x
Enterprise value 726M 852M 677M 636M 1.17B 76.9B 1.28B 7.88B 3.07B 36.32B 3.2B 3.13B 133B EV / Sales 2025 *
65.8x
EV / Sales 2026 * 196x
Free-Float
79.36%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.26%
1 week+9.20%
Current month+3.83%
1 month+15.33%
3 months-19.32%
6 months+28.38%
Current year+74.31%
More quotes
1 week 3.45
Extreme 3.45
3.86
1 month 3.15
Extreme 3.15
4.06
Current year 2.08
Extreme 2.08
5.55
1 year 2
Extreme 2
5.55
3 years 1.43
Extreme 1.434
5.99
5 years 1.43
Extreme 1.434
16.3
10 years 1.43
Extreme 1.434
16.3
More quotes
Manager TitleAgeSince
Chief Executive Officer 52 30/09/2025
Director of Finance/CFO 60 31/07/2012
Chief Tech/Sci/R&D Officer 55 29/07/2025
Director TitleAgeSince
Director/Board Member 75 31/01/2017
Director/Board Member 62 26/05/2019
Director/Board Member 51 30/04/2024
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-0.26%+9.20%+60.34%-8.43% 848M
-1.74%-5.28%+30.48%+104.87% 54.9B
+2.84%-5.58%+168.85%+957.64% 40.49B
+0.70%+6.60%+61.12%+16.75% 39.05B
+0.28%-0.75%-17.84%-43.63% 23.02B
+2.74%+1.14%+31.45%-36.30% 19.13B
-0.30%+8.84%+83.35%-37.88% 17.81B
+0.51%-0.68%+83.44%+186.34% 13.83B
+0.28%-2.07%+0.11%+358.93% 13.83B
+1.31%-3.33%+123.20% - 12.35B
Average +0.64%-0.05%+62.45%+166.48% 23.53B
Weighted average by Cap. +0.54%-1.65%+65.04%+225.86%
See all sector performances

Financials

2025 *2026 *
Net sales 11.03M 12.95M 10.29M 9.67M 17.84M 1.17B 19.44M 120M 46.59M 552M 48.59M 47.56M 2.01B 3.7M 4.34M 3.45M 3.24M 5.98M 392M 6.52M 40.19M 15.63M 185M 16.3M 15.96M 676M
Net income -169M -198M -158M -148M -273M -17.9B -298M -1.84B -714M -8.45B -744M -728M -30.85B -148M -173M -138M -130M -239M -15.65B -260M -1.6B -624M -7.39B -651M -637M -26.98B
Net Debt - -
More financial data * Estimated data
Logo Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly owned research and development facility.
Employees
84
More about the company
Date Price Change Volume
11/12/25 3.800 -0.26% 293,910
10/12/25 3.810 +4.67% 343,173
09/12/25 3.640 +4.00% 229,934
08/12/25 3.500 +1.45% 167,914
05/12/25 3.450 -2.13% 141,387

Real-time Euronext Paris, December 11, 2025 at 04:55 pm

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.800EUR
Average target price
8.200EUR
Spread / Average Target
+115.79%
Consensus

Quarterly revenue - Rate of surprise